Turmeric, curcumin and psoriasis: the trial was of nanoparticles with a prescription drug, not a spoon of spice

Why turmeric is on the list

Turmeric is the yellow root that colours curry, and curcumin is the compound in it that laboratories have studied for anti-inflammatory activity for decades. Psoriasis is an inflammatory disease. The syllogism writes itself, and it has written itself onto every anti-inflammatory food list for psoriasis, usually as a teaspoon in warm milk or a capsule of extract.

The problem with the syllogism is that the trial cited for it did not give people the spice. It gave them a formulation its investigators had engineered for solubility, stability and predicted intestinal absorption, and that engineering is the part the lists leave out.

There is a second reason the list keeps turmeric, and it is a survey. When the National Psoriasis Foundation asked its members what had helped their skin, eighty-six percent had tried a dietary change, and the additions most often reported as helping were fish oil, vegetables and oral vitamin D ^[4]. That is a record of what people believe worked, gathered after the fact with no comparison group, and it is the same kind of evidence that puts nightshades on the avoid-lists. It tells you what the conversation contains. It does not tell you what turmeric does.

Sources for this section: [4] Dietary Behaviors in Psoriasis: Patient-Reported Outcomes from a U.S. National Survey

What the trial actually gave people

Start with the reason the trial had to be engineered at all. The investigators' own objective was to develop nanoparticles of curcumin and give them orally to people with moderate-to-severe psoriasis in a placebo-controlled, double-blind, randomised trial ^[8]. They did not test the spice or the ordinary extract; they investigated binary systems of curcumin and polymers to optimise solubility and stability, checked the chosen formulation's predicted passive intestinal absorption in a laboratory model before giving it to anyone, and reported on the formulation as much as on the patients ^[8]. That is a drug-development study wearing a kitchen ingredient's name.

The randomised evidence in psoriasis comes from a placebo-controlled, double-blind trial in people with moderate-to-severe disease, defined as a severity index above 10, who were being treated with oral acitretin, a prescription retinoid. The intervention was not turmeric and not ordinary curcumin. The investigators developed nanoparticles of curcumin, nanocrystals stabilised with a polymer at a specific ratio, characterised them by X-ray diffraction, calorimetry and electron microscopy, tested their stability and modelled their intestinal absorption, and then gave those to the treatment group ^[8].

Their conclusion was that curcumin nanoparticles represent an effective adjuvant therapy in moderate-to-severe psoriasis patients treated with oral acitretin, improving their serum lipid profile ^[8]. Read each qualifier. Nanoparticles, not spice, at 3 g a day for 12 weeks. Adjuvant, meaning added to a drug, not instead of one. In people on acitretin, with the serum lipid profile reported as one of the outcomes. A trial of an engineered pharmaceutical formulation in a treated population is real evidence, and it is evidence about that formulation in that population.

Sources for this section: [8] Curcumin nanoparticles potentiate therapeutic effectiveness of acitrein in moderate-to-severe psoriasis patients and control serum cholesterol levels

The pooled analysis: one cytokine, low-to-moderate certainty

In 2025 a network meta-analysis pooled twenty-one randomised trials of dietary supplements in plaque psoriasis, 1463 patients in all, covering vitamin D, fish oil, selenium, probiotics, curcumin, a whey extract and micronutrients. Its curcumin finding was narrow: curcumin reduced interleukin-22, one of the signalling molecules involved in psoriasis. The headline results on the severity index belonged to vitamin D, and the review's overall judgement was that no supplement dominated across outcomes and the certainty of the evidence was low to moderate because of heterogeneity and imprecision ^[7]. Adverse events were comparable across the supplements studied ^[7].

A reduction in a cytokine is a laboratory result. It is the kind of finding that justifies a bigger trial; it is not the kind of finding that justifies a purchase. The review's authors say as much, calling for larger confirmatory trials with standardised dosing and longer follow-up ^[7].

Sources for this section: [7] Effectiveness and safety of dietary supplements in the adjunctive treatment of psoriasis: a systematic review and network meta-analysis

What the professional guidance does with it

As far as the guidance cited on this page goes, nothing. The joint dermatology guidelines of care for psoriasis review alternative medicine as part of their scope, with the dermatologist's role framed as monitoring and educating patients on benefits and risks ^[3]. The National Psoriasis Foundation's dietary review filed select foods and nutrients under low-quality data that may affect psoriasis, with weight reduction and a conditional gluten-free diet as its recommendations ^[2]. The clinical-practice review of nutrition in psoriasis spends its recommendations on the Mediterranean diet, calorie restriction and gluten ^[5]. A 2025 systematic review of dietary recommendations names the patterns and nutrients with possible benefit, curcumin not among them, and states plainly that high-quality evidence is lacking ^[6].

Four current documents whose purpose is to translate evidence into advice, and none of them, as cited here, translates the nanoparticle trial into a recommendation for turmeric. Whatever their reasons, the chain from that trial to a supplement in a shop has to pass through the formulation, the dose and the co-prescribed drug, and a spoon of spice passes through none of them.

Sources for this section: [2] Dietary Recommendations for Adults With Psoriasis or Psoriatic Arthritis From the Medical Board of the National Psoriasis Foundation: A Systematic Review · [3] Joint AAD-NPF guidelines of care for psoriasis · [5] Nutrition and Psoriasis: The Latest Evidence and How to Approach Nutrition in Clinical Practice · [6] Evidence-based dietary recommendations for patients with psoriasis: A systematic review

The spice, the capsule and the decision

Turmeric is a good spice; it belongs in a dhal, a curry, a tagine and a roast cauliflower, and it costs nothing to keep in the cupboard. What it does for the skin is a question no evidence cited here has asked: the one trial tested an engineered formulation at 3 g a day, which is not the dose or the form a kitchen delivers.

A curcumin capsule is a different decision, and it is one to make with the dermatologist who is treating you. The evidence that exists is for an engineered formulation added to a prescription drug in people with moderate-to-severe disease; a supplement bought alone is not that, and whether it is worth trying alongside your treatment, at what dose and with what to watch for, is a clinical conversation. Adverse events in the pooled trials were comparable across the supplements studied ^[7], which is a statement about the trials' reporting, not a safety verdict on any capsule bought alone.

The dietary change with trial evidence in psoriasis is a whole pattern, not an ingredient: the Mediterranean diet, which in a 16-week randomised trial improved the severity index by a between-group difference of -3.4, with nine of 19 people on it reaching a 75% reduction against none of the controls ^[1]. Turmeric is a spice that can sit inside that pattern and is not a substitute for it. The free seven-day psoriasis week on this site is that pattern cooked; the turmeric in it is there as seasoning, which is what it is.

Sources for this section: [1] Mediterranean Diet and Patients With Psoriasis: The MEDIPSO Randomized Clinical Trial · [7] Effectiveness and safety of dietary supplements in the adjunctive treatment of psoriasis: a systematic review and network meta-analysis